SCHEMBL4215552

SCHEMBL4215552

COc1ccc(-c2ccc(C(=O)O)c(Nc3ccc(F)cc3)c2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 10/20 0.53
AKR1C2 P52895 10/20 0.53
ACLY P53396 1/20 0.51
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
USP2 O75604 1/20 0.48
PABPC1 P11940 1/20 0.48
KDM4E B2RXH2 1/20 0.48
APAF1 O14727 1/20 0.48
RECQL P46063 1/20 0.48
CASP6 P55212 1/20 0.48
CACNA1B Q00975 1/20 0.48
APBA1 Q02410 1/20 0.48
MCL1 Q07820 1/20 0.48
CASP8 Q14790 1/20 0.48
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
IDO1 P14902 1/20 0.47
NPC1 O15118 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4216992 0.89 AKR1C3 (0.54) AKR1C3AKR1C2ACLYKDM4EAPAF1
SCHEMBL4210556 0.86 AKR1C3 (0.57) AKR1C3AKR1C2ACLYKMT2AMEN1
SCHEMBL4223753 0.84 CLCN2 (0.56) AKR1C3AKR1C2KMT2AMEN1USP2
SCHEMBL4225674 0.83 AKR1C3 (0.71) AKR1C3AKR1C2KMT2AMEN1MAPT
SCHEMBL4222396 0.83 XDH (0.52) AKR1C3AKR1C2ACLYKMT2AMEN1
SCHEMBL4221155 0.82 AKR1C3 (0.54) AKR1C3AKR1C2ACLYKDM4EAPAF1
SCHEMBL4226484 0.82 XDH (0.54) AKR1C3AKR1C2ACLYMAPT
SCHEMBL4216624 0.81 GRIK1 (0.58) AKR1C3AKR1C2ACLYKMT2AMEN1
SCHEMBL4216592 0.80 AKR1C3 (0.65) AKR1C3AKR1C2
SCHEMBL4223054 0.79 AKR1C3 (0.59) AKR1C3AKR1C2ACLYKDM4EMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 AKR1C3 105/4885AKR1C2 287/4885ACLY 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.